Skip to main content
OGI
NASDAQ Life Sciences

Organigram Replaces Auditor After Adverse Opinion on Internal Controls

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
7
Price
$1.45
Mkt Cap
$195.947M
52W Low
$0.85
52W High
$2.24
Market data snapshot near publication time

summarizeSummary

Organigram Global Inc. has replaced its auditor, PKF O'Connor Davies, LLP, with PricewaterhouseCoopers LLP, following an adverse opinion on the company's internal control over financial reporting for the past two fiscal years.


check_boxKey Events

  • Auditor Change Announced

    Organigram Global Inc. has terminated PKF O'Connor Davies, LLP as its auditor and intends to appoint PricewaterhouseCoopers LLP (PwC) at its next annual general meeting.

  • Adverse Opinion on Internal Controls

    The predecessor auditor, PKF O'Connor Davies, LLP, issued an adverse opinion on the effectiveness of the company's internal control over financial reporting for the fiscal years ended September 30, 2025, and September 30, 2024, due to material weaknesses.

  • Unqualified Financial Statements

    Despite the adverse opinion on internal controls, the predecessor auditor issued unqualified reports on the company's consolidated financial statements for the fiscal years ended September 30, 2025, and September 30, 2024.

  • No Reportable Events

    The company stated there were no 'reportable events' (as defined by National Instrument 51-102) between the Corporation and the Predecessor Auditor.


auto_awesomeAnalysis

Organigram Global Inc. has changed its auditor from PKF O'Connor Davies, LLP to PricewaterhouseCoopers LLP. This change is significant because the predecessor auditor issued an adverse opinion on the effectiveness of the company's internal control over financial reporting for the fiscal years ended September 30, 2025, and September 30, 2024, due to material weaknesses. While the financial statements themselves received unqualified reports, an adverse opinion on internal controls indicates potential risks in the reliability of financial reporting processes. The appointment of PwC, a 'Big Four' firm, could signal an effort to strengthen financial controls and oversight, but the underlying material weaknesses remain a concern for investors.

At the time of this filing, OGI was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.9M. The 52-week trading range was $0.85 to $2.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed OGI - Latest Insights

OGI
Apr 17, 2026, 8:33 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
OGI
Apr 15, 2026, 7:50 PM EDT
Filing Type: 6-K
Importance Score:
9
OGI
Mar 30, 2026, 9:55 PM EDT
Filing Type: 6-K
Importance Score:
8
OGI
Mar 23, 2026, 10:10 AM EDT
Filing Type: 6-K
Importance Score:
8
OGI
Mar 09, 2026, 5:14 PM EDT
Filing Type: 6-K
Importance Score:
9
OGI
Mar 05, 2026, 12:27 PM EST
Filing Type: 6-K
Importance Score:
7
OGI
Feb 24, 2026, 11:18 AM EST
Filing Type: 6-K
Importance Score:
7
OGI
Feb 20, 2026, 5:26 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
OGI
Feb 20, 2026, 4:58 PM EST
Filing Type: 6-K
Importance Score:
9
OGI
Feb 19, 2026, 6:10 PM EST
Filing Type: 6-K
Importance Score:
7